Know Cancer

or
forgot password

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide


Phase 3
18 Years
N/A
Not Enrolling
Both
Advanced HCC

Thank you

Trial Information

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide


Inclusion Criteria:



- adequate WBC

- adequate liver and kidney function

- no immunodeficiency

- ECOG < 2

Exclusion Criteria:

- advanced liver cirrhosis

- severe cardiopulmonary diseases

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Frequency of CD4+CD25+regulatory T cells

Outcome Time Frame:

within 8 weeks

Safety Issue:

No

Principal Investigator

Tim F Greten, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Gastroenterology, Medizinische Hochschule Hannover

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

HAN-HCC-002

NCT ID:

NCT00396682

Start Date:

February 2007

Completion Date:

December 2008

Related Keywords:

  • Advanced HCC
  • HCC
  • T cell
  • Carcinoma, Hepatocellular

Name

Location